Internal Medicine

• 
  Post By

  Med Open Press

• Published

  February 2026

Precision Diabetology: Moving Beyond “Type 1 vs Type 2”

As genotyping and phenotyping improve, diabetes classification is becoming more nuanced than a simple binary. Precision approaches aim to match treatment strategy to underlying biology and risk, rather than relying on broad labels alone.

GLP-1 Agonists: Benefit, Trade-offs, and Monitoring

GLP-1 therapies have changed obesity and diabetes care. Alongside efficacy, clinicians and patients still need to understand tolerability (especially GI effects), dosing strategy, and safety monitoring.

The “second act” conversation explores benefits beyond weight—metabolic and cardiovascular impacts—while keeping realistic expectations and follow-up.

Kidneys and Hypertension: Why the Silo is Breaking

Blood pressure and kidney function influence each other. A modern integrated approach reduces fragmentation, aligning risk targets, labs, and medication choices across specialties.

Understanding Hemodialysis: A Beginner-Friendly Overview

When chronic kidney disease progresses, hemodialysis supports essential filtration and fluid balance. Patient education and practical planning can reduce anxiety and improve adherence.

14

MAR

• Internal Medicine

The Silo Is Broken: Why We No Longer Treat Kidneys and Hypertension Separately

Beyond the Scale: GLP-1 Receptor Agonists and the New Frontier of Cardio-Renal-Metabolic Medicine

How a single drug class is rewriting the treatment paradigm for heart failure, sleep apnea, and chronic kidney disease

14

MAR

• Internal Medicine

• 01
• 02